Osteoprotegerin overexpression by breast cancer cells enhances orthotopic and osseous tumor growth and contrasts with that delivered therapeutically.

@article{Fisher2006OsteoprotegerinOB,
  title={Osteoprotegerin overexpression by breast cancer cells enhances orthotopic and osseous tumor growth and contrasts with that delivered therapeutically.},
  author={Jane L. Fisher and Rachel J. Thomas-Mudge and Jan N Elliott and Daphne K. Hards and Natalie A Sims and John Slavin and Thomas J Martin and Matthew T. Gillespie},
  journal={Cancer research},
  year={2006},
  volume={66 7},
  pages={3620-8}
}
Osteoprotegerin (OPG) acts as a decoy receptor for receptor activator of NF-kappaB ligand (RANKL), which is a pivotal molecule required for osteoclast formation. In vitro OPG inhibits osteoclast formation and in vivo (administered as Fc-OPG) it reduces hypercalcemia and the establishment of osteolytic lesions in mouse models of tumor cell growth in bone. Osteolysis can be induced by parathyroid hormone-related protein (PTHrP) produced by breast cancer cells that results in an increased… CONTINUE READING

Citations

Publications citing this paper.
Showing 1-10 of 40 extracted citations

Of bones and noise

View 10 Excerpts
Highly Influenced

Overcoming immunosuppression in bone metastases.

Critical reviews in oncology/hematology • 2017
View 1 Excerpt

References

Publications referenced by this paper.
Showing 1-10 of 33 references

Osteoprotegerin is a receptor for the cytotoxic ligand TRAIL.

The Journal of biological chemistry • 1998
View 12 Excerpts
Highly Influenced

AMG162 increases bone mineral density (BMD) within 1 month in postmenopausal women with low BMD

MR McClung, EM Lewiecki, MA Bolognese
J Bone Miner Res • 2004
View 12 Excerpts
Highly Influenced

Similar Papers

Loading similar papers…